What role does tigecycline's patent play in its high cost?

Short answer: patents help keep tigecycline expensive by delaying generic competition.

What the patent does
- Gives the original developer (Wyeth/Pfizer) a period of market exclusivity for tigecycline (and some related uses/formulations). During this time, no generic versions can enter the market in that jurisdiction.
- This exclusivity lets the company set higher prices to recoup R&D, manufacturing, and regulatory costs.

What patents cover
- Composition-of-matter patent on the tigecycline molecule.
- Patents on formulations (how the drug is made and delivered, e.g., IV formulation).
- Patents on methods of use (which infections to treat) and sometimes manufacturing processes.
- In some markets, data exclusivity (protection of the clinical trial data) can extend protection even after the composition patent expires.

How this affects cost
- With no generics competing, the brand-name drug can maintain higher price levels.
- Once the primary patents and any data exclusivity expire, generics can enter and prices typically drop, though other patents or regulatory protections may still extend some protection in certain markets.

Other factors behind the price
- Antibiotics with narrow indications, hospital-only IV use, and limited patient populations often have higher per-dose prices.
- Manufacturing complexity, supply constraints, and stewardship-driven prescribing (which limits volume) can also influence cost.

If you want, I can outline the current patent/exclusivity status for a specific country or explain how price typically changes after patent expiry.